Literature DB >> 27152262

Stop chronic kidney disease progression: Time is approaching.

Usama Abdel Azim Sharaf El Din1, Mona Mansour Salem1, Dina Ossama Abdulazim1.   

Abstract

Progression of chronic kidney disease (CKD) is inevitable. However, the last decade has witnessed tremendous achievements in this field. Today we are optimistic; the dream of withholding this progression is about to be realistic. The recent discoveries in the field of CKD management involved most of the individual diseases leading the patients to end-stage renal disease. Most of these advances involved patients suffering diabetic kidney disease, chronic glomerulonephritis, polycystic kidney disease, renal amyloidosis and chronic tubulointerstitial disease. The chronic systemic inflammatory status and increased oxidative stress were also investigated. This inflammatory status influences the anti-senescence Klotho gene expression. The role of Klotho in CKD progression together with its therapeutic value are explored. The role of gut as a major source of inflammation, the pathogenesis of intestinal mucosal barrier damage, the role of intestinal alkaline phosphatase and the dietary and therapeutic implications add a novel therapeutic tool to delay CKD progression.

Entities:  

Keywords:  Amyloidosis; Chronic kidney disease; Diabetic nephropathy; Klotho; Micro RNA; Progression

Year:  2016        PMID: 27152262      PMCID: PMC4848149          DOI: 10.5527/wjn.v5.i3.258

Source DB:  PubMed          Journal:  World J Nephrol        ISSN: 2220-6124


  194 in total

1.  Beneficial influence of dietary spices on the ultrastructure and fluidity of the intestinal brush border in rats.

Authors:  Usha N S Prakash; Krishnapura Srinivasan
Journal:  Br J Nutr       Date:  2010-02-24       Impact factor: 3.718

2.  Chronic kidney disease: Statins in chronic kidney disease: time to move on?

Authors:  Richard Haynes; Christoph Wanner
Journal:  Nat Rev Nephrol       Date:  2015-03-24       Impact factor: 28.314

3.  Influence of dietary phosphorus and sulphaguanidine levels on P utilization in rats.

Authors:  R J Moore; P G Reeves; T L Veum
Journal:  Br J Nutr       Date:  1984-05       Impact factor: 3.718

4.  CC chemokine ligand 5/RANTES chemokine antagonists aggravate glomerulonephritis despite reduction of glomerular leukocyte infiltration.

Authors:  Hans-Joachim Anders; Michael Frink; Yvonne Linde; Bernard Banas; Markus Wörnle; Clemens D Cohen; Volker Vielhauer; Peter J Nelson; Hermann-Josef Gröne; Detlef Schlöndorff
Journal:  J Immunol       Date:  2003-06-01       Impact factor: 5.422

5.  Exacerbation of albuminuria and renal fibrosis in subtotal renal ablation model of adiponectin-knockout mice.

Authors:  Koji Ohashi; Hirotsugu Iwatani; Shinji Kihara; Yasuhiko Nakagawa; Noriyuki Komura; Koichi Fujita; Norikazu Maeda; Makoto Nishida; Fumie Katsube; Iichiro Shimomura; Takahito Ito; Tohru Funahashi
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-07-12       Impact factor: 8.311

Review 6.  Therapy for fibrotic diseases: nearing the starting line.

Authors:  Scott L Friedman; Dean Sheppard; Jeremy S Duffield; Shelia Violette
Journal:  Sci Transl Med       Date:  2013-01-09       Impact factor: 17.956

Review 7.  Novel targets of antifibrotic and anti-inflammatory treatment in CKD.

Authors:  Anne-Emilie Declèves; Kumar Sharma
Journal:  Nat Rev Nephrol       Date:  2014-03-25       Impact factor: 28.314

Review 8.  Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis.

Authors:  Tahir Kanji; Mandark Gandhi; Catherine M Clase; Robert Yang
Journal:  BMC Nephrol       Date:  2015-04-19       Impact factor: 2.388

Review 9.  Clinical and economic aspects of sevelamer therapy in end-stage renal disease patients.

Authors:  Shahrzad Ossareh
Journal:  Int J Nephrol Renovasc Dis       Date:  2014-05-08

10.  Changes in fibroblast growth factor 23 levels in normophosphatemic patients with chronic kidney disease stage 3 treated with lanthanum carbonate: results of the PREFECT study, a phase 2a, double blind, randomized, placebo-controlled trial.

Authors:  Pablo Ureña-Torres; Dominique Prié; Karim Keddad; Peter Preston; Paul Wilde; Hong Wan; J Brian Copley
Journal:  BMC Nephrol       Date:  2014-05-05       Impact factor: 2.388

View more
  11 in total

Review 1.  Review of cardiovascular outcomes trials of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists.

Authors:  Emily J North; Jonathan D Newman
Journal:  Curr Opin Cardiol       Date:  2019-11       Impact factor: 2.161

2.  Traditional and Non-traditional Clinical and Biochemical Risk Factors for Altered Kidney Function in Type II Diabetes mellitus Patients.

Authors:  Violeta Valentina Gherdan; Amorin Remus Popa
Journal:  Maedica (Buchar)       Date:  2019-09

3.  Blood pressure and phosphate level in diabetic and non-diabetic kidney disease: Results of the cross-sectional "Low Clearance Consultation" study.

Authors:  Margarida Mendes; Luis Resende; Alves Teixeira; João Correia; Gil Silva
Journal:  Porto Biomed J       Date:  2017-03-30

Review 4.  Diabetic nephropathy: Time to withhold development and progression - A review.

Authors:  Usama A A Sharaf El Din; Mona M Salem; Dina O Abdulazim
Journal:  J Adv Res       Date:  2017-04-21       Impact factor: 10.479

5.  Association of the combination of weight gain after 20 years of age and current obesity with chronic kidney disease in Japan: a cross-sectional study.

Authors:  Hirotaka Ochiai; Takako Shirasawa; Takahiko Yoshimoto; Satsue Nagahama; Mariko Kobayashi; Akira Minoura; Keiichiro Ikeda; Eri Ozaki; Hiromi Hoshino; Akatsuki Kokaze
Journal:  BMJ Open       Date:  2019-06-21       Impact factor: 2.692

Review 6.  The Role of Fibroblast Growth Factor 23 in Inflammation and Anemia.

Authors:  Brian Czaya; Christian Faul
Journal:  Int J Mol Sci       Date:  2019-08-27       Impact factor: 5.923

7.  Effect of Age and Acute-Moderate Intensity Exercise on Biomarkers of Renal Health and Filtration.

Authors:  Jeffrey S Forsse; David Buckley; Ahmed Ismaeel; Kathleen A Richardson; Autumn Oliver; Panagiotis Koutakis
Journal:  Biology (Basel)       Date:  2022-03-30

8.  Klotho alleviates indoxyl sulfate-induced heart failure and kidney damage by promoting M2 macrophage polarization.

Authors:  Jing Lv; Jin Chen; Minjia Wang; Fei Yan
Journal:  Aging (Albany NY)       Date:  2020-05-28       Impact factor: 5.682

9.  Super-resolution microscopy reveals that Na+/K+-ATPase signaling protects against glucose-induced apoptosis by deactivating Bad.

Authors:  Kristoffer Bernhem; Jacopo M Fontana; Daniel Svensson; Liang Zhang; Linnéa M Nilsson; Lena Scott; Hans Blom; Hjalmar Brismar; Anita Aperia
Journal:  Cell Death Dis       Date:  2021-07-27       Impact factor: 8.469

10.  Hepatic Steatosis Index and Chronic Kidney Disease among Middle-Aged Individuals: A Large-Scale Study in Japan.

Authors:  Hirotaka Ochiai; Takako Shirasawa; Takahiko Yoshimoto; Satsue Nagahama; Ken Sakamoto; Minami Azuma; Akatsuki Kokaze
Journal:  Dis Markers       Date:  2021-06-09       Impact factor: 3.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.